NCT02787369
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 10 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion moved earlier from Apr 2026 to Jun 2019
- Eligibility criteria expanded, about 5 words
- Trial completed
- Study completion date changed from estimate of Apr 2027 to Mar 2023
- Notable Primary completion date: Apr 2024 to Apr 2026
- Study completion date: Apr 2026 to Apr 2027
- Notable Primary completion date: Apr 2022 to Apr 2024
- Study completion date: Apr 2023 to Apr 2026
- Study description revised
- Notable Primary completion date: Apr 2021 to Apr 2022v8
- Notable Primary completion date: Apr 2020 to Apr 2021
- Study completion date: Apr 2022 to Apr 2023
Show 4 earlier versionsHide 4 earlier versions
- Notable Primary completion date: Apr 2019 to Apr 2020v6
- Minor Secondary endpoints: details revised at 4 of 4 entriesv5
- Notable Enrollment target: estimated 56 to confirmed 3
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Determining Maximum Tolerated Dose
Timeframe: 2 years
Secondary (4)
Clinical Response Rate
Best Overall Response Rate
Progression Free Survival Rate
Overall Survival Rate
Arms and interventions
Combination of ACY-1215 With IbrutinibExperimental
ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
Combination of ACY-1215 With IdelalisibExperimental
ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
Drugs: ACY-1215, Ibrutinib, Idelalisib
Sites
1 site in 1 country
- Dana Farber Cancer InstituteBoston, Massachusetts, United States